Cited 6 time in
New N-Alkylated Heterocyclic Compounds as Prospective NDM1 Inhibitors: Investigation of In Vitro and In Silico Properties
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kaddouri, Yassine | - |
| dc.contributor.author | Bouchal, Btissam | - |
| dc.contributor.author | Abrigach, Farid | - |
| dc.contributor.author | El Kodadi, Mohamed | - |
| dc.contributor.author | Bellaoui, Mohammed | - |
| dc.contributor.author | Elkamhawy, Ahmed | - |
| dc.contributor.author | Touzani, Rachid | - |
| dc.contributor.author | Abdellattif, Magda H. | - |
| dc.date.accessioned | 2023-04-27T10:40:49Z | - |
| dc.date.available | 2023-04-27T10:40:49Z | - |
| dc.date.issued | 2022-07 | - |
| dc.identifier.issn | 1424-8247 | - |
| dc.identifier.issn | 1424-8247 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/2888 | - |
| dc.description.abstract | A new family of pyrazole-based compounds (1-15) was synthesized and characterized using different physicochemical analyses, such as FTIR, UV-Visible, H-1, C-13 NMR, and ESI/LC-MS. The compounds were evaluated for their in vitro antifungal and antibacterial activities against several fungal and bacterial strains. The results indicate that some compounds showed excellent antibacterial activity against E. coli, S. aureus, C. freundii, and L. monocytogenes strains. In contrast, none of the compounds had antifungal activity. Molecular electrostatic potential (MEP) map analyses and inductive and mesomeric effect studies were performed to study the relationship between the chemical structure of our compounds and the biological activity. In addition, molecular docking and virtual screening studies were carried out to rationalize the antibacterial findings to characterize the modes of binding of the most active compounds to the active pockets of NDM1 proteins. | - |
| dc.format.extent | 19 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | MDPI | - |
| dc.title | New N-Alkylated Heterocyclic Compounds as Prospective NDM1 Inhibitors: Investigation of In Vitro and In Silico Properties | - |
| dc.type | Article | - |
| dc.publisher.location | 스위스 | - |
| dc.identifier.doi | 10.3390/ph15070803 | - |
| dc.identifier.scopusid | 2-s2.0-85133504299 | - |
| dc.identifier.wosid | 000834397100001 | - |
| dc.identifier.bibliographicCitation | Pharmaceuticals, v.15, no.7, pp 1 - 19 | - |
| dc.citation.title | Pharmaceuticals | - |
| dc.citation.volume | 15 | - |
| dc.citation.number | 7 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 19 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
| dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
| dc.subject.keywordPlus | METHIONINE GAMMA-LYASE | - |
| dc.subject.keywordPlus | MOLECULAR DOCKING | - |
| dc.subject.keywordPlus | ANTIMICROBIAL ACTIVITIES | - |
| dc.subject.keywordPlus | ANTIBACTERIAL ACTIVITY | - |
| dc.subject.keywordPlus | BIOLOGICAL EVALUATION | - |
| dc.subject.keywordPlus | CATECHOLASE ACTIVITY | - |
| dc.subject.keywordPlus | AGENTS SYNTHESIS | - |
| dc.subject.keywordPlus | TRIPODAL LIGAND | - |
| dc.subject.keywordPlus | PYRAZOLE | - |
| dc.subject.keywordPlus | DERIVATIVES | - |
| dc.subject.keywordAuthor | synthesis | - |
| dc.subject.keywordAuthor | pyrazole | - |
| dc.subject.keywordAuthor | antibacterial | - |
| dc.subject.keywordAuthor | antifungal | - |
| dc.subject.keywordAuthor | ADME-Tox | - |
| dc.subject.keywordAuthor | molecular docking | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
